Does Aduhelm mark the return of science-based medicine? - podcast episode cover

Does Aduhelm mark the return of science-based medicine?

Aug 19, 202119 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

"While we still lack a complete cause and effect model of Alzheimer’s disease, there is no doubt that the etiology is multifaceted and nonlinear. This accounts for the fact that it takes an incredibly long time for Alzheimer’s disease to develop. I mention this because one of the major problems with FDA approval has always been that it insists on utilizing the same framework and methodology of approving drugs designed to treat long-term diseases as it would with short-term diseases."

Robert Trent is a graduate student who blogs at Medaphysics.

He shares his story and discusses his KevinMD article, "Does the FDA approval of aducanumab mark the return of science-based medicine?" (https://www.kevinmd.com/blog/2021/07/does-the-fda-approval-of-aducanumab-mark-the-return-of-science-based-medicine.html)

For the best experience, listen in Metacast app for iOS or Android